| 发明名称 |
COMBINATION ANTI-ESTROGEN RECEPTOR CANCER THERAPY USING MUC1 PEPTIDES AND CHEMOTHERAPEUTICS |
| 摘要 |
The invention provides for treatment of MUC1+/ERα+/− cancers using an anti-MUC1 therapy, optionally including an anti-ERα therapy. In particular, the invention addresses the treatment of tamoxifen-resistant cancers, using MUC1+, and optionally anti-ERα therapy. |
| 申请公布号 |
US2016058827(A1) |
申请公布日期 |
2016.03.03 |
| 申请号 |
US201414774163 |
申请日期 |
2014.03.10 |
| 申请人 |
DANA-FARBER CANCER INSTITUTE, INC. ;GENUS ONCOLOGY, LLC |
发明人 |
KUFE Donald W.;KHARBANDA Surender |
| 分类号 |
A61K38/07;A61K38/10;A61K38/08;A61K31/138 |
主分类号 |
A61K38/07 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of inhibiting a MUC1-positive/ERα-positive tumor cell in a subject comprising administering to said subject a MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC (SEQ ID NO:4), wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence, wherein said tumor cell exhibits primary resistance to tamoxifen. |
| 地址 |
Boston MA US |
